Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.

@article{Verweij2003ImatinibM,
  title={Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.},
  author={Jaap Verweij and A. T. Van Oosterom and J P Blay and Ian Judson and Sjoerd Rodenhuis and Winette T A van der Graaf and John Radford and Axel le Cesne and P. C. W. Hogendoorn and Eugenio Donato di Paola and Michelle T Brown and Ole Steen Nielsen},
  journal={European journal of cancer},
  year={2003},
  volume={39 14},
  pages={2006-11}
}
The aim of this study was to assess the antitumour response and time to progression (TTP) of patients treated with imatinib mesylate (Glivec, Gleevec, formerly STI-571) who had advanced and/or metastatic gastrointestinal stroma tumours (GIST) or other soft tissue sarcomas (STS). Patients with measurable lesions and adequate organ function were entered. They… CONTINUE READING